OPR - Delayed Quote • USD SVRA Jul 2024 7.500 call (SVRA240719C00007500) Follow 0.7000 0.0000 (0.00%) At close: April 25 at 2:36 PM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for SVRA240719C00007500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: SVRA Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 Savara Announces New Employment Inducement Grant Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update Savara to Present at the Barclays 26th Annual Global Healthcare Conference Savara Inc. (NASDAQ:SVRA): Are Analysts Optimistic? Savara to Present at Two Upcoming Healthcare Conferences Insider Sell: CEO Matthew Pauls Disposes of 84,000 Shares of Savara Inc (SVRA) Savara Introduces aPAP ClearPath™, a GM-CSF Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Savara Added to the NASDAQ Biotechnology Index Savara Inc. (NASDAQ:SVRA) most popular amongst private equity firms who own 41% of the shares, institutions hold 31% Savara to Present at the Piper Sandler 35th Annual Healthcare Conference Savara Reports Third Quarter Financial Results and Provides Business Update
